<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HBB4354DB8D7F4D72BD6006778086519E" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 2391 IH: Medicaid Generic Drug Price Fairness Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-05-18</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 2391</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150518">May 18, 2015</action-date>
			<action-desc><sponsor name-id="C000984">Mr. Cummings</sponsor> (for himself and <cosponsor name-id="N000147">Ms. Norton</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend title XIX of the Social Security Act to require the payment of an additional rebate to the
			 State Medicaid plan in the case of increase in the price of a generic drug
			 at a rate that is greater than the rate of inflation.</official-title>
	</form>
	<legis-body id="H300F91C7F0AE427C9A006A594CBACBAD" style="OLC">
 <section id="H30C088D6806A4632B3AD765A122CDAAC" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Medicaid Generic Drug Price Fairness Act of 2015</short-title></quote>.</text> </section><section id="HC6D6715C62E3453D8F91BCD7A63ED39C"><enum>2.</enum><header>Applying the medicaid additional rebate requirement to generic drugs</header> <subsection id="HA1F512177FCB4EBB8D6895C8719A61EE"><enum>(a)</enum><header>In general</header><text>Section 1927(c)(3) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(c)(3)</external-xref>) is amended—</text>
 <paragraph id="HB2D3FFAB45264BEDA9B37F93EE99D11F"><enum>(1)</enum><text>in subparagraph (A), by striking <quote>The amount</quote> and inserting <quote>Except as provided in subparagraph (C), the amount</quote>; and</text> </paragraph><paragraph id="H58514636034D469C92A9BFB456A8116B"><enum>(2)</enum><text>by adding at the end the following new subparagraph:</text>
					<quoted-block display-inline="no-display-inline" id="H59A721BC83134B4FACB3E9CE40FA8EDF" style="OLC">
						<subparagraph id="H9BD1443004A44E2D9F3AF48E7A129B3C"><enum>(C)</enum><header>Additional rebate</header>
 <clause id="HFDAC4C343DA6437DBFC21FAFB44666BB"><enum>(i)</enum><header>In general</header><text>The amount of the rebate specified in this paragraph for a rebate period, with respect to each dosage form and strength of a covered outpatient drug other than a single source drug or an innovator multiple source drug, shall be increased in the manner that the rebate for a dosage form and strength of a single source drug or an innovator multiple source drug is increased under subparagraphs (A) and (D) of paragraph (2), except as provided in clause (ii).</text>
 </clause><clause id="H0208E39E15A74B158ADFEE9A5C14D257"><enum>(ii)</enum><header>Special rules for application of provision</header><text>In applying subparagraphs (A) and (D) of paragraph (2) under clause (i)—</text> <subclause id="H431CDA7AFE7546B381CEC9C7E17C8235"><enum>(I)</enum><text display-inline="yes-display-inline">the reference in subparagraph (A)(i) of such paragraph to <quote>1990</quote> shall be deemed a reference to <quote>2014</quote>;</text>
 </subclause><subclause id="H28A5E4117A3742D2BDDBD588407771ED"><enum>(II)</enum><text display-inline="yes-display-inline">subject to clause (iii), the reference in subparagraph (A)(ii) of such paragraph to <quote>calendar quarter beginning July 1, 1990</quote> shall be deemed a reference to the <quote>calendar quarter in which the average manufacturer price for the drug is the lowest during the 12-calendar quarter period ending on September 30, 2014</quote>;</text>
 </subclause><subclause id="H8B26BAFBB67B4BB6AA1F907CF7FA1833"><enum>(III)</enum><text display-inline="yes-display-inline">subject to clause (iii), the reference in subparagraph (A)(ii) of such paragraph to <quote>September 1990</quote> shall be deemed a reference to <quote>the last month of such calendar quarter</quote>;</text> </subclause><subclause id="HE18373D5DC6B46F185819E2EFA750FC8"><enum>(IV)</enum><text display-inline="yes-display-inline">the references in subparagraph (D) of such paragraph to <quote>paragraph (1)(A)(ii)</quote>, <quote>this paragraph</quote>, and <quote>December 31, 2009</quote> shall be deemed references to <quote>subparagraph (A)</quote>, <quote>this subparagraph</quote>, and <quote>December 31, 2014</quote>, respectively; and</text>
 </subclause><subclause id="H8A2A5DDB204C4601BF5D798BB4D4643E"><enum>(V)</enum><text>any reference in such paragraph to a <quote>single source drug or an innovator multiple source drug</quote> shall be deemed to be a reference to a drug to which clause (i) applies.</text> </subclause></clause><clause id="HC1213A963FB74B63AE0044EF135300EE"><enum>(iii)</enum><header>Special rule for certain noninnovator multiple source drugs</header><text display-inline="yes-display-inline">In applying paragraph (2)(A)(ii)(II) under clause (i) with respect to a covered outpatient drug that is first sold as a drug other than a single source drug or an innovator multiple source drug after the date that is 3 years before the date of the enactment of this subparagraph, such paragraph shall be applied—</text>
 <subclause id="H986396CAAEB74770B39D0E1E621BDF66"><enum>(I)</enum><text>by substituting <quote>the applicable quarter</quote> for <quote>the calendar quarter beginning July 1, 1990</quote>; and</text> </subclause><subclause id="HFFD9692AC0424B9AAD689E5ED1E706D9"><enum>(II)</enum><text>by substituting <quote>the last month in such applicable quarter</quote> for <quote>September 1990</quote>.</text>
 </subclause></clause><clause id="HA548513CAB3D41C79AEF742DC5F36AA1"><enum>(iv)</enum><header>Applicable quarter defined</header><text display-inline="yes-display-inline">In this subsection, the term <term>applicable quarter</term> means, with respect to a drug described in clause (iii), the fifth full calendar quarter in which the drug is sold as a drug other than a single source drug or an innovator multiple source drug.</text></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="H986BD77E11C144B9B70E249838D1B4E3"><enum>(b)</enum><header>Effective date</header><text>The amendments made by subsection (a) shall apply to rebate periods beginning after December 31, 2014.</text>
			</subsection></section></legis-body>
</bill>


